Celia Oreja-Guevara
Complutense University of Madrid
Internal medicinePathologyIntensive care medicinePhysical therapyPediatricsAdverse effectCohort studyImmunologyObservational studyDiseaseMultiple sclerosisExpanded Disability Status ScaleNatalizumabNeuromyelitis opticaIn patientIncidence (epidemiology)Family medicineClinical trialMedicineCohort
211Publications
37H-index
3,803Citations
Publications 215
Newest
#1Sean J. Pittock (Mayo Clinic)H-Index: 79
#2Kazuo Fujihara (Fukushima Medical University)H-Index: 71
Last. Marcus Yountz (Alexion Pharmaceuticals)H-Index: 2
view all 13 authors...
During PREVENT (a phase 3, randomized, double-blind, placebo-controlled, time-to-event study) and its open-label extension (interim analysis), 33 adults with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-IgG + NMOSD) received eculizumab monotherapy for a median of 2.8 years (range, 14 weeks-5.2 years). At 192 weeks (~4 years), 96% of these patients were free from adjudicated relapses (Kaplan-Meier analysis; 95% confidence interval, 75.7-99.4). During PREVENT,...
Source
Last. Pierre DuquetteH-Index: 58
view all 0 authors...
Source
#1Luis María Sánchez-Gómez (ISCIII: Carlos III Health Institute)H-Index: 5
#2M. Polo-deSantos (ISCIII: Carlos III Health Institute)H-Index: 4
Last. S. Luengo-Matos (ISCIII: Carlos III Health Institute)H-Index: 4
view all 5 authors...
Resumen Introduccion El objetivo es evaluar la eficacia y seguridad de los neuroestimuladores perifericos del ganglio esfenopalatino (GEP) para el tratamiento de la cefalea en racimos cronica refractaria al tratamiento. Desarrollo Revision sistematica de la literatura cientifica. Se identificaron estudios mediante una busqueda en diferentes bases de datos. Las estrategias de busqueda se realizaron hasta el 31 de octubre de 2016, incluyendo ensayos clinicos, revisiones sistematicas o metaanalisis...
Source
#1Peter Rieckmann (FAU: University of Erlangen-Nuremberg)H-Index: 19
#2Diego CentonzeH-Index: 92
Last. Hashem SalloukhH-Index: 1
view all 11 authors...
Background: Gaps in current evidence and guidance leave clinicians with unanswered questions on the use of cladribine tablets for the treatment of multiple sclerosis (MS) in the era of the COVID 19 pandemic, in particular relating to COVID 19 vaccination. Objective: We describe a consensus-based programme led by international MS experts with the aim of supplementing current guidelines and treatment labels by providing timely recommendations relating to COVID 19 vaccination and the use of cladrib...
Source
#1Georgina Arrambide (Autonomous University of Barcelona)H-Index: 20
Last. Mayra Gómez-MorenoH-Index: 1
view all 40 authors...
Objective null To understand COVID-19 characteristics in people with multiple sclerosis (MS) and identify high-risk individuals due to their immunocompromised state resulting from the use of disease-modifying treatments. null Methods null Retrospective and multicenter registry in patients with MS with suspected or confirmed COVID-19 diagnosis and available disease course (mild = ambulatory; severe = hospitalization; and critical = intensive care unit/death). Cases were analyzed for associations ...
Source
#1Irene Moreno-Torres (FUI: Foundation University, Islamabad)H-Index: 2
Last. Yolanda AladroH-Index: 7
view all 28 authors...
Background null Limited information is available on incidence and outcomes of COVID-19 in patients with multiple sclerosis (MS). This study investigated the risks of SARS-CoV-2 infection and COVID-19-related outcomes in patients with MS, and compared these with the general population. null Methods null A regional registry was created to collect data on incidence, hospitalization rates, intensive care unit (ICU) admission and death in patients with MS and COVID-19. National government outcomes an...
Source
INTRODUCTION: For more than a decade, following the ECTRIMS Congress, the Post-ECTRIMS Meeting has been held in Spain, where neurologists with expertise in multiple sclerosis (MS) from all over the country meet to review the most relevant latest developments presented at the ECTRIMS congress (on this occasion held together with ACTRIMS) AIM: This article, published in two parts, summarises the presentations that took place at the Post-ECTRIMS Meeting, held online on 16 and 17 October 2020 DEVELO...
Source
#1Oscar FernándezH-Index: 26
#4A. AlonsoH-Index: 13
Last. Tamara Castillo-TriviñoH-Index: 14
view all 24 authors...
INTRODUCTION: For more than a decade, following the ECTRIMS Congress, the Post-ECTRIMS Meeting has been held in Spain, where neurologists with expertise in multiple sclerosis (MS) from all over the country meet to review the most relevant latest developments presented at the ECTRIMS congress (on this occasion held together with ACTRIMS). AIM: This article, published in two parts, summarises the presentations that took place at the Post-ECTRIMS Meeting, held online on 16 and 17 October 2020. DEVE...
BACKGROUND AND OBJECTIVES Research in Multiple Sclerosis (MS) has recently focused on extracting knowledge from real-world clinical data sources. This type of data is more abundant than data produced during clinical trials and potentially more informative about real-world clinical practice. However, this comes at the cost of less curated and controlled data sets. In this work we aim to predict disability progression by optimally extracting information from longitudinal patient data in the real-w...
Source
#1Wei Zhen Yeh (Monash University)H-Index: 2
#2Putu Ayu Widyastuti (Monash University)
Last. Vilija Jokubaitis (Monash University)H-Index: 25
view all 46 authors...
OBJECTIVE To investigate pregnancy-related disease activity in a contemporary multiple sclerosis (MS) cohort. METHODS Using data from the MSBase Registry, we included pregnancies conceived after 31 Dec 2010 from women with relapsing-remitting MS or clinically isolated syndrome. Predictors of intrapartum relapse, and postpartum relapse and disability progression were determined by clustered logistic regression or Cox regression analyses. RESULTS We included 1998 pregnancies from 1619 women with M...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.